Tenaya Therapeutics Partners with Alnylam for Genetic Research
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ALNY?
Source: Benzinga
- Collaboration Agreement: Tenaya Therapeutics has entered into a research collaboration with Alnylam Pharmaceuticals focused on identifying genetic targets for cardiovascular diseases, with Tenaya set to validate up to 15 gene targets and potentially receive $10 million upfront and up to $1.13 billion in milestone payments, significantly enhancing its research capabilities.
- Technical Advantages: Tenaya employs human-induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) for high-throughput genetic target identification, alongside engineered heart tissue and preclinical in vivo models for validation, having generated over 150 genetic targets that contribute to the development of clinical-stage candidates.
- Clinical Trial Progress: In December 2025, Tenaya shared interim data from the RIDGE-1 Phase 1b/2 trial of TN-401 gene therapy for rare inherited heart disease, reporting safety, biopsy, and arrhythmia results from three patients, indicating the therapy's potential in treating such conditions.
- Market Performance Analysis: Despite a 31.20% increase to 76 cents, Tenaya's stock remains 29.1% and 23.6% below its 100-day and 200-day simple moving averages, indicating a bearish trend in the medium to long term, with analysts generally rating it as a
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALNY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALNY
Wall Street analysts forecast ALNY stock price to rise
17 Analyst Rating
14 Buy
3 Hold
0 Sell
Strong Buy
Current: 327.300
Low
351.00
Averages
479.53
High
580.00
Current: 327.300
Low
351.00
Averages
479.53
High
580.00
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Health Care Stocks Decline, NYSE Health Care Index Drops 2.3%
- Overall Decline in Health Care Stocks: On Thursday afternoon, health care stocks broadly fell, with the NYSE Health Care Index dropping 2.3%, reflecting market concerns about the sector's outlook, which could impact investor confidence and lead to capital outflows.
- Diminished Market Sentiment: The downward trend in the health care sector may be linked to overall economic uncertainty, as investors grow increasingly wary of potential policy changes and regulatory pressures, thereby affecting stock performance.
- Investor Reactions: In light of the decline in health care stocks, investors may reassess their portfolios, seeking more defensive asset allocations to mitigate potential market volatility and risks.
- Uncertain Industry Outlook: The short-term performance of the health care sector may be influenced by multiple factors, including policy changes and fluctuations in market demand, prompting investors to closely monitor developments to adjust their investment strategies.
See More
Tenaya Therapeutics Partners with Alnylam for Genetic Research
- Collaboration Agreement: Tenaya Therapeutics has entered into a research collaboration with Alnylam Pharmaceuticals focused on identifying genetic targets for cardiovascular diseases, with Tenaya set to validate up to 15 gene targets and potentially receive $10 million upfront and up to $1.13 billion in milestone payments, significantly enhancing its research capabilities.
- Technical Advantages: Tenaya employs human-induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) for high-throughput genetic target identification, alongside engineered heart tissue and preclinical in vivo models for validation, having generated over 150 genetic targets that contribute to the development of clinical-stage candidates.
- Clinical Trial Progress: In December 2025, Tenaya shared interim data from the RIDGE-1 Phase 1b/2 trial of TN-401 gene therapy for rare inherited heart disease, reporting safety, biopsy, and arrhythmia results from three patients, indicating the therapy's potential in treating such conditions.
- Market Performance Analysis: Despite a 31.20% increase to 76 cents, Tenaya's stock remains 29.1% and 23.6% below its 100-day and 200-day simple moving averages, indicating a bearish trend in the medium to long term, with analysts generally rating it as a
See More
Tenaya Therapeutics Partners with Alnylam for Up to $1.1B Cardiovascular Drug Collaboration
- Collaboration Agreement: Tenaya Therapeutics has signed a research collaboration with Alnylam Pharmaceuticals worth up to $1.1 billion, aimed at discovering 15 genetic targets associated with cardiovascular diseases, showcasing the company's strong potential in the biotech sector.
- Upfront Payment and Milestone Rewards: Under the terms, Tenaya will receive up to $10 million as an upfront payment and is eligible for an additional $1.13 billion based on development and commercial milestones, significantly enhancing the company's liquidity and supporting its R&D activities.
- Strategic Importance: CEO Faraz Ali emphasized that this multi-target collaboration underscores Tenaya's commitment to rigorous science and leverages its proprietary capabilities to drive the discovery and development of cardiovascular candidates, further solidifying its position in the biopharmaceutical industry.
- Positive Market Reaction: Following the announcement of the collaboration, Tenaya's stock rose approximately 10% in premarket trading, reflecting investor optimism regarding the potential of this partnership, which may enhance the company's market recognition and future growth prospects.
See More
Tenaya and Alnylam Enter Research Collaboration Agreement
- Collaboration Agreement: Tenaya Therapeutics has signed a research collaboration agreement with Alnylam Pharmaceuticals to discover potential human genetic targets for cardiovascular disease, marking a strategic partnership in gene therapy.
- Funding Support: Tenaya will receive up to $10 million in upfront payments along with reimbursement for related costs, ensuring sufficient funding for its research activities during the two-year validation period.
- Potential Earnings: Should all genetic targets lead to approved therapeutics, Tenaya could be eligible for up to $1.13 billion in development and commercial milestone payments, significantly enhancing its financial position and market competitiveness.
- Stock Price Reaction: In pre-market trading on Nasdaq, Tenaya's shares rose by 11.8% to $0.6499, reflecting positive market expectations and increased investor confidence regarding the collaboration.
See More
Tenaya and Alnylam Forge Collaboration for Genetic Heart Disease Targets
- Collaboration Overview: Tenaya Therapeutics has entered into a research collaboration agreement with Alnylam Pharmaceuticals to identify and validate up to 15 gene targets for cardiovascular diseases, highlighting a strategic synergy in advancing disease-modifying treatments in heart disease.
- Financial Support: Under the agreement, Tenaya will receive up to $10 million in upfront payments along with reimbursement for related costs during the two-year validation period, and could earn up to $1.13 billion in milestone payments if all targets lead to successful therapeutics, significantly enhancing its financial position.
- Enhanced Technical Capabilities: Tenaya has successfully identified over 150 genetic targets using human induced pluripotent stem cell-derived cardiomyocytes and high-throughput screening technologies, which not only boosts its research efficiency but also lays a solid foundation for future clinical candidates.
- Strategic Implications: This collaboration not only showcases Tenaya's innovative capabilities in heart disease treatment but also has the potential to drive the development of novel transformational medicines by leveraging Alnylam's RNA interference technology, positioning Tenaya favorably in the competitive biopharmaceutical market.
See More
Tenaya and Alnylam Forge Collaboration for Genetic Heart Disease Targets
- Collaboration Overview: Tenaya Therapeutics has entered into a research collaboration agreement with Alnylam Pharmaceuticals to identify and validate up to 15 gene targets for cardiovascular diseases, showcasing a powerful alliance in the field of gene therapy.
- Financial Support: Tenaya will receive up to $10 million in upfront payments, along with reimbursement for related costs during the two-year validation period, and could earn up to $1.13 billion in milestone payments if all targets lead to successful therapeutics, significantly enhancing its liquidity.
- Technological Edge: Leveraging human induced pluripotent stem cell-derived cardiomyocytes and high-throughput screening technologies, Tenaya has generated over 150 genetic targets, which will accelerate the development of new therapies and enhance its competitive position in cardiovascular disease treatment.
- Strategic Implications: This collaboration not only demonstrates Tenaya's innovative capabilities in heart disease treatment but also has the potential to meet the growing market demand through the development of transformational therapies, further solidifying its leadership in the biotechnology sector.
See More
Health Care Stocks Decline, NYSE Health Care Index Drops 2.3%
- Overall Decline in Health Care Stocks: On Thursday afternoon, health care stocks broadly fell, with the NYSE Health Care Index dropping 2.3%, reflecting market concerns about the sector's outlook, which could impact investor confidence and lead to capital outflows.
- Diminished Market Sentiment: The downward trend in the health care sector may be linked to overall economic uncertainty, as investors grow increasingly wary of potential policy changes and regulatory pressures, thereby affecting stock performance.
- Investor Reactions: In light of the decline in health care stocks, investors may reassess their portfolios, seeking more defensive asset allocations to mitigate potential market volatility and risks.
- Uncertain Industry Outlook: The short-term performance of the health care sector may be influenced by multiple factors, including policy changes and fluctuations in market demand, prompting investors to closely monitor developments to adjust their investment strategies.
See More
Tenaya Therapeutics Partners with Alnylam for Genetic Research
- Collaboration Agreement: Tenaya Therapeutics has entered into a research collaboration with Alnylam Pharmaceuticals focused on identifying genetic targets for cardiovascular diseases, with Tenaya set to validate up to 15 gene targets and potentially receive $10 million upfront and up to $1.13 billion in milestone payments, significantly enhancing its research capabilities.
- Technical Advantages: Tenaya employs human-induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) for high-throughput genetic target identification, alongside engineered heart tissue and preclinical in vivo models for validation, having generated over 150 genetic targets that contribute to the development of clinical-stage candidates.
- Clinical Trial Progress: In December 2025, Tenaya shared interim data from the RIDGE-1 Phase 1b/2 trial of TN-401 gene therapy for rare inherited heart disease, reporting safety, biopsy, and arrhythmia results from three patients, indicating the therapy's potential in treating such conditions.
- Market Performance Analysis: Despite a 31.20% increase to 76 cents, Tenaya's stock remains 29.1% and 23.6% below its 100-day and 200-day simple moving averages, indicating a bearish trend in the medium to long term, with analysts generally rating it as a
See More
Tenaya Therapeutics Partners with Alnylam for Up to $1.1B Cardiovascular Drug Collaboration
- Collaboration Agreement: Tenaya Therapeutics has signed a research collaboration with Alnylam Pharmaceuticals worth up to $1.1 billion, aimed at discovering 15 genetic targets associated with cardiovascular diseases, showcasing the company's strong potential in the biotech sector.
- Upfront Payment and Milestone Rewards: Under the terms, Tenaya will receive up to $10 million as an upfront payment and is eligible for an additional $1.13 billion based on development and commercial milestones, significantly enhancing the company's liquidity and supporting its R&D activities.
- Strategic Importance: CEO Faraz Ali emphasized that this multi-target collaboration underscores Tenaya's commitment to rigorous science and leverages its proprietary capabilities to drive the discovery and development of cardiovascular candidates, further solidifying its position in the biopharmaceutical industry.
- Positive Market Reaction: Following the announcement of the collaboration, Tenaya's stock rose approximately 10% in premarket trading, reflecting investor optimism regarding the potential of this partnership, which may enhance the company's market recognition and future growth prospects.
See More
Tenaya and Alnylam Enter Research Collaboration Agreement
- Collaboration Agreement: Tenaya Therapeutics has signed a research collaboration agreement with Alnylam Pharmaceuticals to discover potential human genetic targets for cardiovascular disease, marking a strategic partnership in gene therapy.
- Funding Support: Tenaya will receive up to $10 million in upfront payments along with reimbursement for related costs, ensuring sufficient funding for its research activities during the two-year validation period.
- Potential Earnings: Should all genetic targets lead to approved therapeutics, Tenaya could be eligible for up to $1.13 billion in development and commercial milestone payments, significantly enhancing its financial position and market competitiveness.
- Stock Price Reaction: In pre-market trading on Nasdaq, Tenaya's shares rose by 11.8% to $0.6499, reflecting positive market expectations and increased investor confidence regarding the collaboration.
See More
Tenaya and Alnylam Forge Collaboration for Genetic Heart Disease Targets
- Collaboration Overview: Tenaya Therapeutics has entered into a research collaboration agreement with Alnylam Pharmaceuticals to identify and validate up to 15 gene targets for cardiovascular diseases, highlighting a strategic synergy in advancing disease-modifying treatments in heart disease.
- Financial Support: Under the agreement, Tenaya will receive up to $10 million in upfront payments along with reimbursement for related costs during the two-year validation period, and could earn up to $1.13 billion in milestone payments if all targets lead to successful therapeutics, significantly enhancing its financial position.
- Enhanced Technical Capabilities: Tenaya has successfully identified over 150 genetic targets using human induced pluripotent stem cell-derived cardiomyocytes and high-throughput screening technologies, which not only boosts its research efficiency but also lays a solid foundation for future clinical candidates.
- Strategic Implications: This collaboration not only showcases Tenaya's innovative capabilities in heart disease treatment but also has the potential to drive the development of novel transformational medicines by leveraging Alnylam's RNA interference technology, positioning Tenaya favorably in the competitive biopharmaceutical market.
See More
Tenaya and Alnylam Forge Collaboration for Genetic Heart Disease Targets
- Collaboration Overview: Tenaya Therapeutics has entered into a research collaboration agreement with Alnylam Pharmaceuticals to identify and validate up to 15 gene targets for cardiovascular diseases, showcasing a powerful alliance in the field of gene therapy.
- Financial Support: Tenaya will receive up to $10 million in upfront payments, along with reimbursement for related costs during the two-year validation period, and could earn up to $1.13 billion in milestone payments if all targets lead to successful therapeutics, significantly enhancing its liquidity.
- Technological Edge: Leveraging human induced pluripotent stem cell-derived cardiomyocytes and high-throughput screening technologies, Tenaya has generated over 150 genetic targets, which will accelerate the development of new therapies and enhance its competitive position in cardiovascular disease treatment.
- Strategic Implications: This collaboration not only demonstrates Tenaya's innovative capabilities in heart disease treatment but also has the potential to meet the growing market demand through the development of transformational therapies, further solidifying its leadership in the biotechnology sector.
See More
